Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-na€ ıve relapsed/refractory cHL. All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed. The median age was 32 years. Most had nodular sclerosis subtype, Eastern Cooperative Oncology Group performance status 0-1 and advanced stage disease. The median progression-free survival (PFS) was 5Á6 months and median overall survival (OS) was 37Á2 months. The overall response rate was 56% (29% complete response; 27% partial response). 61% reached SCT: 34% immediately post-BV and 27% following an inadequate BV response but were salvaged and underwent deferred SCT. Patients consolidated with SCT had a superior PFS and OS to those not receiving SCT (P < 0Á001). BV is an effective, non-toxic bridge to immediate SCT in 34% and deferred SCT in 27%. 39% never reached SCT with a PFS of 3Á0 months, demonstrating the unmet need to improve outcomes in those unsuitable for SCT post-BV.
Summary
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-na€ ıve relapsed/refractory cHL. All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed. The median age was 32 years. Most had nodular sclerosis subtype, Eastern Cooperative Oncology Group performance status 0-1 and advanced stage disease. The median progression-free survival (PFS) was 5Á6 months and median overall survival (OS) was 37Á2 months. The overall response rate was 56% (29% complete response; 27% partial response). 61% reached SCT: 34% immediately post-BV and 27% following an inadequate BV response but were salvaged and underwent deferred SCT. Patients consolidated with SCT had a superior PFS and
Introduction
Classical Hodgkin lymphoma (cHL) is typically a highly chemosensitive and curable B-cell malignancy, with approximately 2000 new cases annually in the UK . Patients with primary refractory or relapsed disease after first line therapy are uncommon but represent a significant challenge, as do those who fail first line salvage. These scenarios represent clear areas of unmet need where the optimal therapeutic approach is unknown.
Brentuximab vedotin (BV) is a novel anti-CD30 monoclonal antibody conjugated to monomethyl auristatin-E, an antimicrotubule cytotoxic agent. BV has been in routine use in the UK since 2012 under two of its three licenced indications; (i) relapse after autologous stem cell transplant (ASCT) and (ii) failure of two prior lines of therapy in patients unsuitable for ASCT or multi-agent chemotherapy. Data from the Memorial Sloan Kettering Cancer Center indicate that patients who fail to achieve a negative functional imaging scan have a short event-free survival after subsequent ASCT (Moskowitz et al, 2010) . For this reason, many clinicians deem patients in less than complete metabolic response (CMR) after salvage chemotherapy to be unsuitable for ASCT. Further salvage treatment is usually given to induce or deepen responses to enable SCT (autologous or, in some cases, allogeneic SCT). In recent UK practice, patients deemed at high risk of ASCT-failure (typically having a positive positron emission tomography (PET) scan after standard salvage chemotherapy) have been managed according to a response-adjusted transplantation algorithm including the use of T-cell depleted (alemtuzumab conditioned) allogenic SCT consolidation (Thomson et al, 2013) . In a large retrospective series, this approach produced an encouraging 3-year progression-free survival (PFS) of 68% and a 'current' PFS post-donor lymphocyte infusion rate of 80%. This impressive long term disease control with relatively minimal toxicity led to adoption of this approach as standard in many centres and also informed the design of the UK National Cancer Research Network-sponsored PAIRED trial to evaluate outcomes of allogeneic transplant following second or subsequent salvage in patients failing to achieve complete response to first line salvage. The results of this trial are awaited and some patients treated in this way have been included in the current study.
We retrospectively assessed BV outcomes in patients fit but not suitable for SCT, together with the outcome post-SCT (autologous and allogenic) and BV toxicity in a large retrospective UK wide analysis (n = 99).
Material and methods

Patient characteristics
This was a retrospective, multicentre study in patients with relapsed or refractory cHL treated with BV monotherapy at 9 large UK centres between May 2011 and July 2016. Patients were eligible if they were transplant na€ ıve, had received at least 2 prior lines of treatment, and had received BV with the intention of undergoing subsequent SCT consolidation. Data at diagnosis and relapse were collected from hospital records by the treating physician and included; age, gender, lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al, 1982) , extranodal disease, B symptoms, Ann Arbor stage, disease bulk (>10 cm), histological subtype, and risk factors for poor PFS at first relapse (haemoglobin, extranodal disease, B symptoms, Ann Arbor stage), and treatment details for prior treatment lines. Treatment data included best overall response rate (ORR) by PET-computed tomography (CT) or CT alone, duration of first remission and total number of therapy lines prior to BV. Radiotherapy was typically included within a combined treatment modality approach and hence was not included as a separate line of treatment.
Adverse event (AE) data were collected including allergic reactions, cytopenias, neutropenic fever (NF), non-neutropenic fever (NNF), and peripheral neuropathy. AE grades were identified wherever available according to Common Toxicity Criteria For Adverse Events (CTCAE) v 4Á03 (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickRefe rence_8.5x11.pdf). Patient follow-up was censored at the most recent hospital visit or death. The data were locked and analysed in September 2016.
Treatment and statistical analysis
Patients were treated with BV monotherapy dosed at 1Á8 mg/ kg once every three weeks until SCT consolidation, progression, toxicity or death from any cause. PFS was calculated from the initiation of BV to the time of relapse, disease progression, death, or censored at the date of last follow-up. Overall survival (OS) was calculated from the initiation of BV monotherapy to date of death and censored at the date of last follow-up. Responses to treatment were analysed by either PET-CT or standard CT according to local investigator discretion. Cox regression was used to determine univariate predictors of PFS. Independent predictors were identified using multivariate Cox regression. All potential predictors were included in the initial multivariate model, followed by backward selection with the Akaike information criterion (AIC; Burnham & Anderson, 2003) . Fractional polynomials were used to allow for non-linear effects of continuous variables (Royston & Altman, 1994) . Following initial model selection, each excluded variable was added back to the model one at a time, to ensure this did not improve model fit. Testing was undertaken for pairwise interactions between variables in the final model, using a threshold for inclusion of P < 0Á01. All analyses were performed in Stata 14 (StataCorp, College Station, TX, USA).
Results
Ninety-nine patients met the eligibility criteria and were included in the study. Baseline characteristics are summarised in Table I . The median age was 32 years (range 13-70 years) with an equal gender distribution (male 45%; female 55%). Most patients had nodular sclerosis histological subtype (84%), a pre-therapy ECOG performance status of 0-1 (94%) and advanced stage disease (71%) at presentation. Bulky disease (defined as disease >10 cm at any site) was present in 21%. Table II summarises pre-and post-BV treatment. Table III summarises treatment response by line of therapy. Most patients (74%) received ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) induction, either 2-4 cycles with involved field radiotherapy in early stage disease or 6 cycles with bleomycin omitted in a minority (4%) of more recently treated, interim PET-negative patients. Seven patients (7%) escalated intensity following a positive interim PET to escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, prednisolone, procarbazine) or BEACOPP-14. The ORR to first line therapy was 76% (CR/CRu/CMR 44%; PR/PMR 31%) and the median length of first remission in evaluable patients was 6 months (range 0Á7-74 months). Response rates incrementally decreased with subsequent lines of chemotherapy pre-BV [second line; ORR 48% (CR 10%; PR 38%) and third line; ORR 39% (CR 11%; PR 28%)].
Second line therapy was most commonly ESHAP (etoposide, high dose cytarabine, methylprednisolone, cisplatin) (42%) or DHAP (dexamethasone, high dose cytarabine, cisplatin) (24%). IGEV (Ifosfamide, gemcitabine, vinorelbine), ICE (ifosfamide, carboplatin, etoposide) and IVE (ifosfamide, epirubicin, etoposide) were all also regularly used second line regimens. Mini-BEAM (carmustine, etoposide, cytarabine, melphalan)/mini-LEAM (lomustine, etoposide, cytarabine, melphalan) and GEM-P (gemcitabine, cisplatin, methylprednisolone) were the most common third line. Of the total 
Outcomes after BV monotherapy
Ninety-nine patients were treated with BV, and their outcomes are summarised in Fig 1. The median time from prior therapy to starting BV was 2Á5 months (range 0Á7-34Á8 months). 96 patients were evaluable for primary response assessment; 3 patients developed dose-limiting toxicities and did not undergo radiological response assessment.
As assessed by the local physician, the best radiological ORR for all BV patients recorded was 56% (CR 29%, PR 27%) after a median of 4 cycles (range 1-9). The ORR was 53% (CR 29%, PR 24%; n = 68) when BV was used third line, 65% (CR 43%, PR 22%; n = 23) when BV was used fourth line, and 60% (CR 60%, PR 0%; n = 5) when used fifth line. The median number of delivered cycles was 4 (range 1-9). Thirty-four patients (34%) underwent consolidation SCT immediately following successful BV therapy. Prior to ASCT, patients (n = 15) were in CR (64%) or PR (36%). Prior to alloSCT, patients (n = 19) were in CR (68%), PR (22%) or SD (11%). The ORR to BV for all patients ultimately receiving a SCT was 77% (CR 45%, PR 32%) and 66% (CR 42%, PR 24%) for autoSCT and alloSCT respectively. Twenty-seven patients (27%) did not respond sufficiently well to BV to proceed immediately to SCT but underwent successful subsequent therapy followed by deferred SCT. Post-BV treatment in order of frequency and subsequent transplant rate were: mini-BEAM/mini-LEAM (n = 19, 65% SCT), other therapy [including ChlVPP (chlorambucil, vinblastine, prednisolone, procarbazine), combined modality therapy, and clinical trials] (n = 19, 26% SCT), bendamustine (n = 18, 38% SCT), gemcitabine-based therapy (n = 9, 33% SCT), radiotherapy (n = 9, 44% SCT) and DECC (n = 3, 0% SCT).
Thirty-eight patients (38%) did not proceed to SCT at any time. This included 8% (n = 8) who received BV followed by no further therapy and 30% (n = 30) who received BV followed by additional therapy. Typically, patients did not proceed to SCT because of inadequate treatment response [stable or progressive disease (n = 24)]. Of the 38 unconsolidated patients, 10 had an initial PR to BV, but this was short-lived, with a median PFS of only 3Á6 months.
Median follow up from the start of BV was 12Á0 months (0Á4-56Á7 months). Median PFS for all patients was 5Á6 months [95% confidence interval (CI) 4Á4-12Á2 months] (Fig 2A) and median OS for all patients was 37Á2 months (95% CI 18Á3 months -not reached (NR)) (Fig 2B) . Patients consolidated with either an autologous or allogeneic SCT at any time had a superior PFS (Fig 2C) and OS ( Fig 2D) (P < 0Á001 for autologous and allogeneic SCT compared to patients that did not receive a consolidative SCT). The
outcomes were as follows: no SCT [median PFS 3Á0 months (95% CI 2Á5-4Á4) and median OS 12Á2 months (95% CI 8Á1-18Á3 months)] versus autologous SCT [median PFS NR (95% CI 17Á0 months -NR) and median OS NR (95% CI 27Á0 months -NR)] versus allogeneic SCT [median PFS NR (95% CI 5Á6 months -NR) and median OS NR (95% CI 37Á2 months -NR)].
Patients with an improved initial depth of remission to BV translated that response into an improved PFS (Fig 2E) . Patients that required additional chemotherapy following BV pre-SCT had a similar outcome compared to patients achieving a response deemed adequate to proceed to SCT post-BV with no further chemotherapy (Fig 2F) .
Median OS and PFS for these subgroups are also summarised in Table SI.  Table IV summarises the findings of the univariate and multivariate analysis. Univariate predictors of PFS following BV treatment for all patients were baseline pre-therapy performance status at diagnosis ECOG 0 vs. 1 [Hazard ratio (HR) 2Á19 (95% CI 1Á23-3Á92; P = 0Á008], baseline ECOG 0 vs. ≥2 [HR 3Á93 (95% CI 1Á32-11Á65; P = 0Á014)], haemoglobin at first relapse [continuous variable HR 0Á77 (95% CI 0Á65-0Á92; P = 0Á004)] and extranodal disease at first relapse [HR 1Á86 (95% CI 1Á11-3Á14; P = 0Á020)]. ECOG 0 vs. 1 at baseline and haemoglobin at first relapse factors remained statistically significant following multivariate analysis.
Table V describes the AEs reported by local physicians during BV monotherapy. Causality and CTCAE v 4Á03 grading was formally assessed where possible given the retrospective nature of this study. BV was generally well tolerated, with no AEs reported in 63 (64%) of the 99 patients. The most common reported AEs were neutropenia (grade 1-2 n = 9; grade 3-4 n = 6; not known n = 2), anaemia (n = 7; all grade 1), non-neutropenic infection (grade 1-2 n = 5; grade 3-4 n = 4; grade 5 n = 1) and sensory peripheral neuropathy (grade 1-2 n = 7; grade 3-4 n = 2). There were no previously undescribed AEs attributed to BV.
Discussion
There are very limited published outcome data on the efficacy of BV as a bridge to transplant (summarised in Table VI ). The ORR to BV given in the second line treatment setting was 68% (CR 35%; PR 33%) in a phase II trial of 37 patients (Chen et al, 2015) and ranged from 30-71% in the third or higher treatment line in small studies of up to 30 patients (Forero-Torres et al, 2012; Gibb et al, 2013; Sasse et al, 2013; Onishi et al, 2015; Zinzani et al, 2015) . BVenabled immediate ASCT rates ranged from 30-75% in responding patients achieving at least PR. Our data therefore represents the largest retrospective report on the outcomes of BV in transplant eligible patients with relapsed or refractory cHL. In the real-world UK setting, BV produced an ORR of 56%, including 29% complete response rate (including CMR/CR/CRu) and 27% partial response rate (including PMR/PR). One third (34%) of patients proceeded directly to consolidation SCT after a median of 4 cycles of BV, and a further 27% underwent deferred SCT after additional treatment. Patients undergoing SCT entered durable remissions, with median PFS and OS not reached, albeit after a relatively short median follow-up of 12 months in this study. These results suggest that clinical benefit is maintained by SCT consolidation post-BV, highlighting the efficacy of BV in this difficult-to-treat population and confirming its role in the treatment pathway as an effective bridge to SCT in a third of patients with high risk SCTnaive, predominantly refractory cHL.
Response rates recorded in our cohort are consistent with that reported in the literature and summarised in Table VI. Patients achieving a complete response had more durable remissions with the median duration of remission not reached. In contrast, patients with an initial PR following BV had a short median PFS of 6Á5 months (95% 4Á7-NR).
An overall PFS for all patients of 5Á6 months (95% CI 4Á4-12Á2 months) is, however, modest. This is reflected in the fact that nearly half of patients consolidated with a SCT required at least 1 further line of salvage therapy post-BV before SCT. Our data also identified a large group of therapy It is not possible to conclude from these data which type of SCT consolidation is superior. The higher ORR to BV in patients receiving autologous SCT (ORR 77% vs. ORR 66% for allogeneic SCT) may have had some influence over the seemingly improved PFS curve compared to those receiving allogeneic SCT. There was no OS difference between the two strategies and type of SCT was very dependent on physician and centre preference within the cohort as a whole rather than direct patient characteristics per se. Our study was not designed to answer the question of whether alternative treatment options are superior to BV or which consolidation SCT strategy is best, however it is noteworthy that the overall and complete response rates to third line therapy were superior for BV compared to standard treatment (ORR 53% vs. 39%, CR 29% vs. 11%), and the BVbridged immediate SCT rate of 34% is consistent with the published data (see Table IV ). It is impossible to know whether these patients would have responded to these agents if they were given earlier in the disease course or whether BV treatment in some way conditioned the disease to favour response to subsequent therapy. Overall, BV was well tolerated in this setting and this highlights the value of relatively non-toxic regimens in the preparation for more toxic SCT subsequent therapy.
Univariate and multivariate analyses were performed to provide potential predictors of outcome in patients treated with BV monotherapy. We note that patients with a lower haemoglobin and those of male gender had an inferior outcome. Patients who are anaemic are often so as a result of prior lines of therapy and a substantial disease burden and it is likely these are key factors in predicting overall outcome. It is less clear why males had an inferior outcome in our series and this result requires confirmation in an independent series. Patients with a superior ECOG performance status (prior to any therapy) had an overall superior outcome, however these data must be interpreted with caution given the retrospective design of this study.
Other potential weaknesses of our retrospective study include the lack of centralised pathology review of biopsies at diagnosis or relapse, a lack of formal radiological reporting according to published criteria Cheson et al, 2014) and the lack of prospective reporting of AEs and documentation of causality. Onishi et al (2015) 14 Unsuitable for ASCT because refractory disease (n = 9), comorbidity (n = 4) or other reasons (n = 1).
ORR 71% (10):CR 36% (5), PR 36% (5) 36% (5); ASCT (4), alloSCT (1) Sasse et al (2013) 20 Unsuitable for ASCT (median prior lines 3, range 1-7) including 10 transplant-na€ ıve patients from study SG035-0001 and 10 transplant-na€ ıve patients from study SG035-0002.
3 ORR 30% (6): CR 10% (2) PR 20% (4) 75% (3) AlloSCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; BV, brentuximab vedotin; C(M)R, complete (metabolic) response; FDG, 18 F-fluorodeoxyglucose; ORR, overall response rate; PD, progressive disease; PET, positron emission tomography; PR, partial response; SCT, stem cell transplantation; SD, stable disease.
In summary, BV delivers a third of patients to SCT in a non-toxic manner and requiring no further lines of therapy pre-SCT. A further 27% are salvaged post-BV with additional chemotherapy to enable SCT. The remaining 39% that do not reach SCT have very poor outcomes, with PFS of 3Á0 months and demonstrate the unmet need to improve outcomes in those unsuitable for SCT.
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